Overview

Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study

Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Hybrigenics Corporation
Treatments:
Cholecalciferol
Imatinib Mesylate